Abstract
In recent years, the simple paradigm of adipose tissue as merely a fat store is rapidly evolving into a complex paradigm of this tissue as multipotential secretory organ, partitioned into a few large depots, including visceral and subcutaneous location, and many small depots, associated with a variety of organs in the human body. The major secretory compartment of adipose tissue consists of adipocytes, fibroblasts, and mast cells. These cells, using endocrine, paracrine and autocrine pathways, secrete multiple bioactive molecules, conceptualized as adipokines or adipocytokines. This review examines current information in adipobiology of various diseases besides obesity and related diseases such as type 2 diabetes, metabolic syndrome, and cardiovascular disease. Finally, we emphasize the possibilities for adipokine-targeted pharmacology in adiponectin (Acrp30, apM1, AdipoQ, GBP28), angiotensin II, estrogens, nerve growth factor, tumor necrosis factor-a, and also adipose mast cells.
Keywords: adipobiology, adipokines, adipokine targeted pharmacology, adipose tissue, adiponectin, angiotensin II, adipose mast cells
Current Pharmaceutical Design
Title: Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology
Volume: 9 Issue: 12
Author(s): G. N. Chaldakov, I. S. Stankulov, M. Hristova and P. I. Ghenev
Affiliation:
Keywords: adipobiology, adipokines, adipokine targeted pharmacology, adipose tissue, adiponectin, angiotensin II, adipose mast cells
Abstract: In recent years, the simple paradigm of adipose tissue as merely a fat store is rapidly evolving into a complex paradigm of this tissue as multipotential secretory organ, partitioned into a few large depots, including visceral and subcutaneous location, and many small depots, associated with a variety of organs in the human body. The major secretory compartment of adipose tissue consists of adipocytes, fibroblasts, and mast cells. These cells, using endocrine, paracrine and autocrine pathways, secrete multiple bioactive molecules, conceptualized as adipokines or adipocytokines. This review examines current information in adipobiology of various diseases besides obesity and related diseases such as type 2 diabetes, metabolic syndrome, and cardiovascular disease. Finally, we emphasize the possibilities for adipokine-targeted pharmacology in adiponectin (Acrp30, apM1, AdipoQ, GBP28), angiotensin II, estrogens, nerve growth factor, tumor necrosis factor-a, and also adipose mast cells.
Export Options
About this article
Cite this article as:
Chaldakov N. G., Stankulov S. I., Hristova M. and Ghenev I. P., Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology, Current Pharmaceutical Design 2003; 9 (12) . https://dx.doi.org/10.2174/1381612033455152
DOI https://dx.doi.org/10.2174/1381612033455152 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text
Current Vascular Pharmacology Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development
Current Angiogenesis (Discontinued) Effect of Inhibition of Intestinal Cholesterol Absorption on the Prevention of Cholesterol Gallstone Formation
Medicinal Chemistry Diabetic Cardiomyopathy: Electromechanical Cellular Alterations
Current Vascular Pharmacology Achilles Tendon in Diabetes
Current Diabetes Reviews Functional and Structural Alterations of Large Arteries: Methodological Issues
Current Pharmaceutical Design Metabolic Syndrome as a Modifier of Atherosclerosis in Murine Models
Current Drug Targets Targeting Vascular Redox Biology Through Antioxidant Gene Delivery: A Historical View and Current Perspectives
Recent Patents on Cardiovascular Drug Discovery Insulin Resistance and Hypertension
Current Hypertension Reviews Editorial (Thematic Issue: Protection, Repair and Regeneration of Achybreaky Heart)
Current Drug Targets Vascular, Oxidative, and Synaptosomal Abnormalities During Aging and the Progression of Type 2 Diabetes
Current Neurovascular Research Nitric Oxide: News from Stem Cells to Platelets
Current Medicinal Chemistry New Technologies: Non-Hormonal Female Contraception
Current Women`s Health Reviews Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Deep Vein Thrombosis and Pulmonary Embolism in the Apixaban Era: From Bench to Bedside
Current Drug Targets Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Current Pharmaceutical Design Endothelin-1 Actions on Vascular Smooth Muscle Cell Functions As a Target for the Prevention of Atherosclerosis
Current Vascular Pharmacology Implications of the Obesity Epidemic for Statin Therapy: Shifting Cholesterol Metabolism to a High Synthesis and Low Dietary Absorption State
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Mechanisms Underlying St. Johns Wort Drug Interactions
Current Drug Metabolism